Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Current Liabilities (2020 - 2025)

Xeris Biopharma Holdings' Total Current Liabilities history spans 6 years, with the latest figure at $109.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 9.09% year-over-year to $109.6 million, compared with a TTM value of $109.6 million through Dec 2025, up 9.09%, and an annual FY2025 reading of $109.6 million, up 9.09% over the prior year.
  • Total Current Liabilities for Q4 2025 was $109.6 million at Xeris Biopharma Holdings, down from $116.2 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $116.2 million in Q3 2025, with the low at $37.3 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $82.7 million, with a median of $80.6 million recorded in 2023.
  • Year-over-year, Total Current Liabilities soared 180.21% in 2021 and then decreased 10.24% in 2024.
  • Tracing XERS's Total Current Liabilities over 5 years: stood at $79.0 million in 2021, then dropped by 6.86% to $73.6 million in 2022, then grew by 29.3% to $95.2 million in 2023, then grew by 5.52% to $100.4 million in 2024, then grew by 9.09% to $109.6 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Total Current Liabilities are $109.6 million (Q4 2025), $116.2 million (Q3 2025), and $95.2 million (Q2 2025).